NCT01822925 - Study of DA-9801 to Treat Diabetic Neuropathy | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Diabetic Neuropathy

Interventions

DRUG

DA-9801 300mg

300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.

DRUG

DA-9801 600mg

600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.

DRUG

DA-9801 900mg

900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.

DRUG

Placebo

Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.

Trial Locations (14)

12208

Albany Medical Center, Albany

21205

Johns Hopkins University, Baltimore

29464

Coastal Carolina Research Center, Mt. Pleasant

33401

Metabolic Research Institute, Inc., West Palm Beach

33511

PAB Clinical Research, Brandon

75230

KRK Research, Dallas

75231

North Texas Endocrine Center, Dallas

77074

Houston Foot & Ankle Care, Houston

84107

Wasatch Clinical Research, Salt Lake City

90712

Center for United Research, Inc., Lakewood

98057

Rainier Clinical Research Center, Inc., Renton

94598-3347

Diablo Clinical Research, Walnut Creek

06460

Clinical Research Consulting, LLC, Milford

02740

Novex Clinical Research, Inc., New Bedford